SNY Sanofi
- 48.170
- +0.210+0.44%
- 49.499
- +1.329+2.76%
Sanofi News
Sanofi Price Target Lowered to EUR 85 From EUR 90 at Deutsche Bank
Deutsche Bank Keeps Their Sell Rating on Sanofi (SNYNF)
Berenberg Bank Maintains Sanofi(SNY.US) With Buy Rating, Maintains Target Price $63
Berenberg Bank Remains a Buy on Sanofi (SNY)
Berenberg Bank Sticks to Their Buy Rating for Sanofi (SNYNF)
Sanofi (SNYNF) Gets a Hold From J.P. Morgan
OSE Immunotherapeutics Names Chief Corporate Affairs, Investor Relations Officer
Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China
Sanofi Unveils $1 Billion China Investment to Boost Production
Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest In?
Intron Health Downgrades Sanofi to Hold, Lowers PT
Sanofi's Chief Digital Officer Says Remote Work Means Employees Lose the 'Serendipity' Needed to Innovate
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)
Sanofi Inaugurates $800m Healthcare Manufacturing Facility in SG
Sanofi Opens New $600 Million Vaccines Facility in Singapore
Pharmaceutical giant Sanofi has invested nearly 0.6 billion dollars to build a factory in Singapore to produce vaccines.
French pharmaceutical giant Sanofi announced on Wednesday that it will build a new factory in Singapore to produce vaccines and other pharmaceuticals to enhance preparedness for emergencies, including potential pandemics. According to a statement, the factory named Modulus is being constructed with an investment of 0.8 billion Singapore dollars (almost 0.6 billion US dollars) in the Biopharmaceutical Park in Tuas, Singapore. It can simultaneously produce up to four types of vaccines or biopharmaceuticals and is expected to be fully operational by mid-2026, creating 200 technical jobs in Singapore. The company stated that Modulus can also be reconfigured within days to switch between technical platforms.
Sanofi (SNY.US)/Regeneron (REGN.US) Dupilumab Injection approved again for clinical treatment of pure moss disease in China
A new clinical trial implied consent has been granted for the duperimabd injection declared by Sanofi (SNY.US).
Bird Flu Found In Raw Milk Leads To Recall In California
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement...
No Data
